Is nausea a common side effect of buspirone (Buspar)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Nausea a Common Side Effect of Buspar?

Yes, nausea is a common side effect of buspirone (Buspar), occurring in approximately 8% of patients in controlled clinical trials, compared to 5% with placebo. 1

Evidence from FDA Drug Labeling

The FDA-approved drug label for Buspar clearly identifies nausea as one of the most commonly observed adverse events associated with buspirone use 1. In pooled data from 17 controlled clinical trials involving 477 patients:

  • Nausea occurred in 8% of buspirone-treated patients versus 5% on placebo
  • Nausea was listed among the gastrointestinal disturbances that caused 1.2% of patients to discontinue treatment during premarketing trials
  • The drug label specifically notes that nausea, along with dizziness, headache, nervousness, and lightheadedness, represents the "more commonly observed untoward events" not seen at equivalent rates in placebo patients 1

Supporting Research Evidence

Multiple clinical studies corroborate nausea as a frequent side effect:

  • A meta-analysis of buspirone safety found nausea among the most frequently reported adverse events across both BID and TID dosing regimens 2
  • In patients with generalized anxiety disorder and mild depression, buspirone-treated patients reported significantly more nausea than placebo patients (p < .05) 3
  • A study in major depression reported gastrointestinal effects in 55% of buspirone patients versus 37% on placebo, with nausea being a primary component 4
  • A 2024 systematic review and meta-analysis confirmed gastric distress as significantly more common with buspirone (OR = 1.97,95% CI: 1.03-3.78) compared to placebo 5

Clinical Context

Nausea from buspirone is typically mild to moderate and often self-limiting, though it can occasionally be severe enough to warrant discontinuation 6. In a recent retrospective study of Williams syndrome patients, only 1 of 24 patients (4%) discontinued buspirone due to nausea and vomiting, while 13% experienced nausea that did not require stopping the medication 6.

Important Caveats

  • The incidence of nausea appears dose-dependent in some studies
  • Nausea typically occurs within the first weeks of treatment
  • When nausea occurs alongside fever, myalgia, or arthralgia, consider hypersensitivity reaction rather than simple side effect (though this guidance is from azathioprine literature and may not directly apply) 7
  • The route of administration matters: intranasal buspirone abuse may produce different or enhanced effects 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.